SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Little benefit from pharmacological treatments is observed in patients101; whilst pharmacochaperones could potentially correct mutation‐related protein folding defects and DAT surface expression,104 such approaches are mutation‐specific, as opposed to a gene supplementation strategy, which could treat a broader spectrum of DTDS patients.